Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12559795rdf:typepubmed:Citationlld:pubmed
pubmed-article:12559795lifeskim:mentionsumls-concept:C0062527lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C0681842lld:lifeskim
pubmed-article:12559795lifeskim:mentionsumls-concept:C2713304lld:lifeskim
pubmed-article:12559795pubmed:issue11-12lld:pubmed
pubmed-article:12559795pubmed:dateCreated2003-1-31lld:pubmed
pubmed-article:12559795pubmed:abstractTextSixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39 mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.lld:pubmed
pubmed-article:12559795pubmed:languageenglld:pubmed
pubmed-article:12559795pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:citationSubsetIMlld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12559795pubmed:statusMEDLINElld:pubmed
pubmed-article:12559795pubmed:monthMarlld:pubmed
pubmed-article:12559795pubmed:issn0264-410Xlld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:BertinoJoseph...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:NafzigerAnne...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:DrusanoGeorge...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:RamseyKeith...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:KimMyong-JinM...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:KeyserlingHar...lld:pubmed
pubmed-article:12559795pubmed:authorpubmed-author:HarroClayton...lld:pubmed
pubmed-article:12559795pubmed:copyrightInfoCopyright 2002 Elsevier Science Ltd.lld:pubmed
pubmed-article:12559795pubmed:issnTypePrintlld:pubmed
pubmed-article:12559795pubmed:day7lld:pubmed
pubmed-article:12559795pubmed:volume21lld:pubmed
pubmed-article:12559795pubmed:ownerNLMlld:pubmed
pubmed-article:12559795pubmed:authorsCompleteYlld:pubmed
pubmed-article:12559795pubmed:pagination1174-9lld:pubmed
pubmed-article:12559795pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:meshHeadingpubmed-meshheading:12559795...lld:pubmed
pubmed-article:12559795pubmed:year2003lld:pubmed
pubmed-article:12559795pubmed:articleTitleRevaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.lld:pubmed
pubmed-article:12559795pubmed:affiliationClinical Pharmacology Research Center, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326-1394, USA.lld:pubmed
pubmed-article:12559795pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12559795pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12559795pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12559795pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12559795pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12559795pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12559795lld:pubmed